Analysts express confidence in AstraZeneca's 'transformed' pipeline

10 February 2017

Despite an initial blip, shares in AstraZeneca (LSE: AZN) have climbed by 8% since the Anglo-Swedish pharma major announced its 2016 results last week, reaching £46.12 ($57.57) by Friday lunchtime.

As always, there was talk of the strength of the company’s pipeline, though in this case it was more than just optimistic rhetoric, according to a pair of healthcare research analysts at the investment bank Cantor Fitzgerald.

"The company has reacted to evolving data generated internally and elsewhere to maximize the potential of MYSTIC to deliver a positive outcome which is more likely to be realized fully in 2018 with the overall survival co-primary endpoint"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK